Effect of experimental diabetes and glucagon on cAMP-dependent protein kinase in rat liver
- PMID: 192620
- DOI: 10.1007/BF00745144
Effect of experimental diabetes and glucagon on cAMP-dependent protein kinase in rat liver
Abstract
Liver protein kinase was determined in the absence and presence of cAMP4. Experimental alloxan diabetes resulted in a decrease in total protein kinase (+cAMP) and an increase in the activity ratio (-cAMP) divided by (+cAMP) in liver. Insulin treatment of diabetic rats reversed the observed changes in protein kinase in liver. Glucagon administered in vivo to normal rats caused an increase in the activity ratio and a decrease in total protein kinase activity in liver. The changes are similar to those in diabetes. A decrease in the ratio of insulin to glucagon in diabetes may account for the changes in protein kinase observed.
Similar articles
-
Influence of alloxan-diabetes and insulin on liver protein kinase.Arch Int Physiol Biochim. 1974 Dec;82(5):984-5. Arch Int Physiol Biochim. 1974. PMID: 4142731 No abstract available.
-
Effects of glucagon and insulin on the cyclic AMP binding capacity of hepatocyte cyclic AMP-dependent protein kinase.Mol Cell Biochem. 1987 Jan;73(1):37-44. doi: 10.1007/BF00229374. Mol Cell Biochem. 1987. PMID: 3027531
-
Phosphorylase activation hypersensitivity in hearts of diabetic rats.Am J Physiol. 1984 Feb;246(2 Pt 1):E134-40. doi: 10.1152/ajpendo.1984.246.2.E134. Am J Physiol. 1984. PMID: 6320671
-
Streptozotocin-induced diabetes decreases the cyclic AMP binding activity of the regulatory subunit of type I cAMP-dependent protein kinase from rat liver.Biochem Biophys Res Commun. 1983 Dec 28;117(3):794-802. doi: 10.1016/0006-291x(83)91667-4. Biochem Biophys Res Commun. 1983. PMID: 6320816
-
Regulation of hepatic HMG-CoA reductase in vivo by reversible phosphorylation.Biochim Biophys Acta. 1987 Feb 18;927(2):223-8. doi: 10.1016/0167-4889(87)90138-8. Biochim Biophys Acta. 1987. PMID: 3545301 Review. No abstract available.
Cited by
-
The Transcription Profile Unveils the Cardioprotective Effect of Aspalathin against Lipid Toxicity in an In Vitro H9c2 Model.Molecules. 2017 Jan 31;22(2):219. doi: 10.3390/molecules22020219. Molecules. 2017. PMID: 28146135 Free PMC article.